Primus In News
Tarnished by cough syrup deaths, India’s pharma industry tries to look beyond the stupor
21-07-2023
Nilaya Varma, Co-Founder and CEO of Primus Partners shares his views on the impact of the COVID-19 pandemic and the Russia-Ukraine war on vaccine exports from India, especially to African and Commonwealth of Independent States (CIS) countries. In addition, he stresses that the increasing cost of raw materials and the withdrawal of GST exemption has exacerbated challenges for Indian pharma companies. Read Now!
Explore Related Insights
- LG Electronics India IPO gets fully subscribed on Day 1, GMP signals strong listing: Should you apply?
- Canara HSBC Life IPO subscribed 9% on Day 1, GMP declines: Should you apply?
- Railways' capex meets targets, likely to remain at the same level
- Union Budget may tweak customs duties, ensure ease of import compliance
